Selected article for: "fatality rate and high rate"

Author: Falzarano, Darryl; de Wit, Emmie; Martellaro, Cynthia; Callison, Julie; Munster, Vincent J.; Feldmann, Heinz
Title: Inhibition of novel ß coronavirus replication by a combination of interferon-a2b and ribavirin
  • Document date: 2013_4_18
  • ID: tgngoea8_3
    Snippet: The rapid identification of therapeutics is a high priority as there is currently no specific therapy or vaccine for nCoV and the resulting disease has been severe with a high case-fatality rate. The clinical experience from SARS suggests that a number of interventions including ribavirin with and without corticosteroids [12] [13] [14] , ribavirin with protease inhibitors 15, 16 and interferon (alfacon-1) with corticosteroids 17 may improve outco.....
    Document: The rapid identification of therapeutics is a high priority as there is currently no specific therapy or vaccine for nCoV and the resulting disease has been severe with a high case-fatality rate. The clinical experience from SARS suggests that a number of interventions including ribavirin with and without corticosteroids [12] [13] [14] , ribavirin with protease inhibitors 15, 16 and interferon (alfacon-1) with corticosteroids 17 may improve outcome, but a definitive treatment regimen was not clearly established 18 . Here we address the effectiveness in vitro of two antiviral drugs, interferon-a2b (IFN-a2b) and ribavirin, in an attempt to identify a therapeutic approach that can be immediately utilized in the clinic to benefit future cases.

    Search related documents:
    Co phrase search for related documents
    • high priority and result disease: 1
    • high priority and specific therapy: 1, 2, 3, 4
    • high priority and therapeutic approach: 1
    • outcome improve and rapid identification: 1
    • outcome improve and result disease: 1, 2, 3
    • outcome improve and SARS clinical experience: 1
    • outcome improve and specific therapy: 1, 2, 3, 4, 5, 6
    • outcome improve and therapeutic approach: 1, 2, 3, 4, 5
    • protease inhibitor and result disease: 1, 2
    • protease inhibitor and specific therapy: 1, 2, 3
    • protease inhibitor and therapeutic approach: 1, 2, 3, 4
    • rapid identification and result disease: 1, 2
    • rapid identification and specific therapy: 1
    • rapid identification and therapeutic approach: 1
    • rapid identification and therapeutic rapid identification: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • result disease and specific therapy: 1
    • result disease and therapeutic approach: 1, 2
    • specific therapy and therapeutic approach: 1, 2, 3, 4, 5, 6, 7, 8
    • specific therapy and vaccine specific therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40